Besides several changes in HAART were needed due to resistance or persisting replication. After the last change in HAART (darunavirritonavir),voriconazole C 0 decreased to 0.25 mg/L (50% decrease). Eventually, ranitidine was replaced by esomeprazole 40 mg IV BID. Three days later, voriconazole C 0 increased 14-fold and voriconazole dose could be reduced by 50% to 100 mg (2.5 mg/kg) BID. There were no other medication changes. Subsequent voriconazole C 0 stayed within the therapeutic range. Results: Voriconazole systemic exposure depends on various factors among which CYP 450 activity influenced by genetic polymorphisms and DDI. Our patient was heterozygous for the CYP2C19*17 variant allele, which has been associated with lower voriconazole AUC compared with wild-type individuals. However, her phenotype indicated a reduced activity of CYP2C19.
PP135-PharmaComeTabolomiCS for iNdiVidualized TreaTmeNT of alCoholiSm: high Serum gluTamaTe leVel iS aSSoCiaTed wiTh PoSiTiVe reSPoNSe To aCamProSaTe TreaTmeNT
D.-S. Choi 1* ; H.W. Nam 2 ; and V. Karpyak 3 1 Pharmacology and Psychiatry; 2 Pharmacology; and 3 Psychiatry, Mayo Clinic College of Medicine, Rochester, United States Introduction: Acamprosate, a homo-taurine analogue, is approved for treatment of alcohol dependence. Meta-analyses favor acamprosate for its ability to support abstinence, which is the most stable type of remission in alcoholics. Yet, only a limited number of treatmentseeking alcoholics use acamprosate, most likely because of individual differences in response and the lack of response predictors. Patients (or Materials) and Methods: We used a pharmacometabolomics approach to investigate metabolic response in serum amino acid metabolites (including acamprosate) between responders and nonresponders to acamprosate treatment. Serum samples were collected before and after 3 months of acamprosate treatment. Efficacy was defined by self-reported abstinence during acamprosate treatment and average γ -glutamyl transferase (GGT) levels at baseline and 3-month follow-up were used to confirm abstinence. Of those, 14 responders and 18 nonresponders comprised an investigation cohort and an additional 30 responders and 28 nonresponders comprised a replication sample. Results: Initial metabolite screening was conducted using 32 alcohol-dependent subjects. Glutamate levels were significantly higher at baseline in the 14 responders compared with the 18 nonresponders [t(30) = 2.7, P < 0.05]. After acamprosate treatment, serum glutamate levels in the responder group significantly decreased compared with baseline [t(26) = 3.3, P < 0.05). Similarly, in a replication sample of 58 additional alcohol-dependent subjects, responders had significantly higher glutamate levels at baseline compared with the nonresponder group [t(88) = 2.8, P < 0.05], which decreased significantly after acamprosate treatment [t(86) = 3.6, P < 0.05]. Conclusion: Our findings suggest that high glutamate levels may be a biomarker to predict the efficacy of acamprosate treatment in alcohol-dependent subjects. Disclosure of Interest: None declared. Tolperisone, a centrally acting muscle relaxant, is used for relieving spasticity of neurological origin and muscle spasm associated with painful locomotor diseases. Tolperisone is mainly metaolized by CYP2D6 and CYP2C19, CYP1A2, and CYP2B6 are also involved in the metabolism of tolperisone. CY2D6 is responsible for variablility of drug response, largely due to genetic polymorphism. Therefore, we investigated the effects of CYP2D6 genetic polymorphism on the pharmacokinetics of tolperisone. Patients (or Materials) and Methods: Thirty healthy Korean subjects were selected and they were divided into 3 different groups according to CYP2D6 genotype, CYP2D6*wt/*wt (*wt= *1 or *2, n = 10), CYP2D6*wt/*10 (n = 10) and CYP2D6*10/*10 (n = 10). After overnight fasting, each subject received a single 150-mg oral dose of tolperisone. Blood samples were collected up to 12 hours after drug intake, and plasma concentrations of tolperisone were determined by using LC-MS/MS analytical system. Results: C max and AUC inf of tolperisone in CYP2D6*10/*10 genotype group was significantly higher than those in CYP2D6*wt/*wt group (P = 0.0007 and P = 0.0002, respectively). Apparent oral clearance (CL/F) of tolperisone in CYP2D6*wt/*10 and CYP2D6*10/*10 group was 64% and 75% lower than that in CYP2D6*wt/*wt group (P < 0.001 and P = 0.0001, respectively). Among 3 genotypes, differences in t 1/2 of tolperisone were not statistically significant. Conclusion: Tolperisone is mainly metabolized by CYP2D6 and CYP2D6 genetic polymorphism has a significant impact on the pharmacokinetics of tolperisone. Disclosure of Interest: None declared.
PP136-geNeTiC PolymorPhiSm of

PP137-effeCTS of The geNeTiC PolymorPhiSmS of humaN mulTidrug aNd ToxiN exTruSioN 1 (hmaTe1/SlC47a1) TraNSPorTer oN The reNal Tubular
SeCreTioN of N1-meThylNiCoTiNamide R. Ogawa * ; T. Mikami; M. Takahashi; and H. Echizen Department of Pharmacotherapy, Meiji Pharmaceutical University, Tokyo, Japan Introduction: Human multidrug and toxin extrusion 1 (hMATE1/SLC47A1) transporter may be involved in the active elimination clearance of many cationic drugs in the kidneys. Scarcity of knowledge about endogenous substrates of hMATE1 appears to hinder exploration of the roles of genetic polymorphisms on the functional activity of hMATE1. Patients (or Materials) and Methods: Fifty-four healthy volunteers (32 males and 22 females; 23 [2] years) underwent 3-hour timedurine collection and blood drawing at the midpoint. Plasma and urinary levels of N 1 -methylnicotinamide (MNA) and creatinine were measured with a liquid chromatography-mass spectrometry system. Renal tubular secretion clearance of MNA (C LTS,MNA ) was calculated by subtracting the renal clearance of creatinine (a substitution of glomerular filtration rate) from that of MNA. Genetic variants of hMATE1/SLC47A1 and another renal cation transporter, hOCT2/SLC22A2, were genotyped by polymerase chain reaction followed by direct sequencing. The protocol of the present study was
